Paul Russo

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Open partial nephrectomy. Personal technique and current outcomes
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Arch Esp Urol 64:571-93. 2011
  2. doi request reprint Patient and caregiver knowledge and utilization of partial versus radical nephrectomy: results of a national kidney foundation survey to assess educational needs of kidney cancer patients and caregivers
    Paul Russo
    Memorial Sloan Kettering Cancer Center, Weill School of Medicine, Cornell School of Medicine, New York, NY 10065, USA
    Am J Kidney Dis 61:939-46. 2013
  3. doi request reprint Oncological and renal medical importance of kidney-sparing surgery
    Paul Russo
    Weill Medical College, Cornell University, New York, NY 10021, USA
    Nat Rev Urol 10:292-9. 2013
  4. ncbi request reprint Localized renal cell carcinoma
    P Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 2:447-55. 2001
  5. ncbi request reprint Functional preservation in patients with renal cortical tumors: the rationale for partial nephrectomy
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Urol Rep 9:15-21. 2008
  6. doi request reprint Multi-modal treatment for metastatic renal cancer: the role of surgery
    Paul Russo
    Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
    World J Urol 28:295-301. 2010
  7. doi request reprint Survival rates after resection for localized kidney cancer: 1989 to 2004
    Paul Russo
    Urology Service, Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:84-96. 2008
  8. ncbi request reprint Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    ScientificWorldJournal 7:768-78. 2007
  9. doi request reprint Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy
    Paul Russo
    Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, N Y 10021, USA
    Urol Clin North Am 35:679-86; viii. 2008
  10. ncbi request reprint Renal cryoablation: a new treatment in need of careful clinical investigation
    Paul Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:286-7. 2006

Detail Information

Publications118 found, 100 shown here

  1. ncbi request reprint Open partial nephrectomy. Personal technique and current outcomes
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Arch Esp Urol 64:571-93. 2011
    ..Widespread education and training in kidney preserving surgical strategies is essential going forward...
  2. doi request reprint Patient and caregiver knowledge and utilization of partial versus radical nephrectomy: results of a national kidney foundation survey to assess educational needs of kidney cancer patients and caregivers
    Paul Russo
    Memorial Sloan Kettering Cancer Center, Weill School of Medicine, Cornell School of Medicine, New York, NY 10065, USA
    Am J Kidney Dis 61:939-46. 2013
    ..Key areas of assessment were patient and caregiver knowledge of risk factors for chronic kidney disease (CKD), including kidney cancer and nephrectomy, and of kidney-sparing surgical options...
  3. doi request reprint Oncological and renal medical importance of kidney-sparing surgery
    Paul Russo
    Weill Medical College, Cornell University, New York, NY 10021, USA
    Nat Rev Urol 10:292-9. 2013
    ..Despite these important advances in understanding, which support the use of partial nephrectomy for the treatment of small renal masses, the technique remains underused...
  4. ncbi request reprint Localized renal cell carcinoma
    P Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 2:447-55. 2001
    ..Whether these new approaches to localized renal tumors will supplement or replace current surgical techniques will depend on the findings of carefully designed and controlled clinical trials...
  5. ncbi request reprint Functional preservation in patients with renal cortical tumors: the rationale for partial nephrectomy
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Urol Rep 9:15-21. 2008
    ..73m2, a level of significant CKD, is 95% after PN, but only 64% after RN. RN should be reserved for patients with massive renal tumors in whom PN is not an option. Increased training in PN and its wider application is essential...
  6. doi request reprint Multi-modal treatment for metastatic renal cancer: the role of surgery
    Paul Russo
    Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
    World J Urol 28:295-301. 2010
    ....
  7. doi request reprint Survival rates after resection for localized kidney cancer: 1989 to 2004
    Paul Russo
    Urology Service, Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:84-96. 2008
    ....
  8. ncbi request reprint Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    ScientificWorldJournal 7:768-78. 2007
    ..This surgical experience provides a contemporary foundation as new targeted therapeutic agents are integrated into the neoadjuvant or adjuvant treatment of locally advanced and metastatic renal cancer...
  9. doi request reprint Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy
    Paul Russo
    Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, N Y 10021, USA
    Urol Clin North Am 35:679-86; viii. 2008
    ..Once effective systemic agents are developed, both metastasectomy and cytoreductive nephrectomy will play greater roles in consolidating clinical responses...
  10. ncbi request reprint Renal cryoablation: a new treatment in need of careful clinical investigation
    Paul Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:286-7. 2006
  11. doi request reprint The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors
    Paul Russo
    Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 35:635-43; vii. 2008
    ..The overzealous use of radical nephrectomy for small renal tumors must now be considered detrimental to the long-term health and safety of the patient with a small renal cortical tumor...
  12. ncbi request reprint Renal tumours: developing understanding leads to developments in surgical treatment
    Paul Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 97:9-10. 2006
  13. ncbi request reprint Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy
    Paul Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 1:26-30. 2004
    ..Despite these advances, the prognosis for patients with metastatic RCC is poor. Studies that examine combinations of surgery and systemic therapy aim to improve survival in this high-risk group...
  14. ncbi request reprint Partial nephrectomy: the rationale for expanding the indications
    Paul Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 9:680-7. 2002
    ..We report preliminary results of partial nephrectomy for renal tumors of > or =4 cm in 39 patients with the intent of extending the indications for kidney-sparing surgery...
  15. ncbi request reprint Open partial nephrectomy: an essential contemporary operation
    Paul Russo
    Department of Urology of Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 3:2-3. 2006
  16. ncbi request reprint Urinary diversion after total pelvic exenteration for rectal cancer
    P Russo
    Department of Surgery, Urology Services, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 6:732-8. 1999
    ..We review a 10-year Memorial Sloan-Kettering Cancer Center experience with urinary diversion in this setting...
  17. ncbi request reprint Salvage radical prostatectomy after radiation therapy and brachytherapy
    P Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Endourol 14:385-90. 2000
    ..Perioperative complications are substantial, with urinary incontinence rates of 40% to 50% and rectal injury rates of 10% to 15%. Long-term disease-free survival rates of 30% to 40% can be expected...
  18. ncbi request reprint Open partial nephrectomy: an essential operation with an expanding role
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Curr Opin Urol 17:309-15. 2007
    ..To describe the rationale for expanding the role of partial nephrectomy in the treatment of renal cortical tumors...
  19. ncbi request reprint Partial nephrectomy achieves local tumor control and prevents chronic kidney disease
    Paul Russo
    Memorial Sloan Kettering Cancer Center, Department of Surgery, Urology Service, 1275 York Avenue, NY, 10021, USA
    Expert Rev Anticancer Ther 6:1745-51. 2006
    ....
  20. doi request reprint The role of surgery in the management of early-stage renal cancer
    Paul Russo
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Medical College, Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 25:737-52. 2011
    ..In this article, the optimum approach to the surgical management of localized renal tumors and its impact on renal function are discussed...
  21. doi request reprint Oncological outcomes of partial nephrectomy for renal carcinoma greater than 4 cm
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Curr Opin Urol 21:362-7. 2011
    ..To provide the clinical evidence and benefits of performing partial nephrectomy for renal tumors greater than 4 cm...
  22. pmc Metastatic renal cell carcinoma risk according to tumor size
    R Houston Thompson
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 182:41-5. 2009
    ..We present our experience with renal cell carcinoma. We evaluated the association between tumor size and the metastasis risk in a large patient cohort...
  23. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
    ..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
  24. doi request reprint Urine neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after kidney surgery
    Preston C Sprenkle
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 190:159-64. 2013
    ..We sought to identify the preoperative clinical features and surgical factors during partial nephrectomy that are associated with renal injury, as measured by increased urine NGAL vs controls...
  25. pmc Tumor size is associated with malignant potential in renal cell carcinoma cases
    R Houston Thompson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 181:2033-6. 2009
    ..We evaluated our experience with renal cortical tumors to determine whether tumor size is associated with malignant histology and/or nuclear grade...
  26. doi request reprint Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma
    Ari Adamy
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 185:433-8. 2011
    ..We analyzed characteristics in patients with recurrent renal cell carcinoma 5 years or later after nephrectomy and determined predictors of survival after recurrence...
  27. pmc Renal cell carcinoma in young and old patients--is there a difference?
    R Houston Thompson
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 180:1262-6; discussion 1266. 2008
    ..We reviewed our experience with young patients with renal cell carcinoma and compared them to their older counterparts...
  28. doi request reprint Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC)
    Jonathan L Silberstein
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 110:1276-82. 2012
    ..When complications were sustained, patients were less likely to receive systemic therapy in a timely fashion. These observations may influence the timing or patient selection for surgery or systemic therapy...
  29. pmc Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease
    Ana M Molina
    Department of Medicine, Genitourinary Oncology Service, Weil Medical College of Cornell University, New York, NY, USA
    Am J Clin Oncol 34:454-9. 2011
    ..Sarcomatoid variant is a spindle cell phenotype of renal cell carcinoma (RCC), which is associated with a poor prognosis. We reviewed outcomes of systemic therapy for metastatic, sarcomatoid-variant RCC...
  30. ncbi request reprint Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
    ..This study analyzes the outcomes of partial cystectomy in a contemporary cohort of patients to identify appropriate selection criteria for the procedure...
  31. ncbi request reprint Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence
    Scott E Eggener
    Genitourinary Oncology Service, Division of Solid Tumor Oncology and Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 24:3101-6. 2006
    ..Prognostic factors for patients with metastatic renal cell carcinoma (RCC) are well established. However, the risk profile is unknown for patients with recurrent RCC after a nephrectomy for localized disease...
  32. ncbi request reprint Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
    ..Overall 5-year disease specific survival is in the range of 16.5% to 95% depending on stage. In this study we evaluated predictors associated with disease recurrence and disease specific survival...
  33. pmc Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study
    William C Huang
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 7:735-40. 2006
    ..We aimed to examine new onset of chronic kidney disease in patients with small, renal cortical tumours undergoing radical or partial nephrectomy...
  34. ncbi request reprint Treatment outcome for metastatic papillary renal cell carcinoma patients
    Ellen A Ronnen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:2617-21. 2006
    ..The current retrospective study sought to define clinical features and outcome data for metastatic papillary RCC...
  35. pmc Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma
    Scott E Eggener
    Department of Urology and Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 180:873-8; discussion 878. 2008
    ..We evaluated the prognostic roles of metastasectomy and an established risk stratification system in patients with disease recurrence following nephrectomy for nonmetastatic renal cell carcinoma...
  36. doi request reprint Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution
    Christopher G Przybycin
    Department of Pathology, Urology Service, Memorial Sloan Kettering Cancer Center New York, NY 10065, USA
    Am J Surg Pathol 35:962-70. 2011
    ..On the basis of this long follow-up on a large number of cases, chromophobes seem to have better clinical outcomes than those reported for clear cell and papillary RCCs...
  37. ncbi request reprint Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma
    Stephen D W Beck
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 11:71-7. 2004
    ..Using a large renal tumor database, we examined the effect of tumor histology on the pattern of metastasis and patient survival...
  38. doi request reprint Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study
    Hikmat A Al-Ahmadie
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 35:949-61. 2011
    ..Both extent and patterns must be considered for a definitive diagnosis...
  39. doi request reprint Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies
    Hikmat A Al-Ahmadie
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:377-82. 2008
    ..Therefore, similar to the clone M75, NB100-417 can be used as a diagnostic and potentially a prognostic marker in CRCC, with the advantage of its commercial availability...
  40. ncbi request reprint Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  41. pmc Positive surgical margins at partial nephrectomy: predictors and oncological outcomes
    Ofer Yossepowitch
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:2158-63. 2008
    ..We combine data from 2 tertiary care intuitions, and report predictors of positive surgical margins and long-term oncological outcomes for patients with positive surgical margins...
  42. ncbi request reprint A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma
    Maximiliano Sorbellini
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 173:48-51. 2005
    ..We developed and performed external validation of a postoperative nomogram for this purpose. We used a prospectively updated database of more than 1,400 patients treated at a single institution...
  43. ncbi request reprint Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
    ..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
  44. doi request reprint Complications after radical and partial nephrectomy as a function of age
    William T Lowrance
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:1725-30. 2010
    ..We determined if the association of age and perioperative outcomes differed between nephrectomy types...
  45. pmc Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma
    A Ari Hakimi
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 63:848-54. 2013
    ..PBRM1, SETD2, and BAP1 are located in close proximity to VHL within a commonly lost (approximately 90%) 3p locus. To date, the clinical and pathologic significance of mutations in these novel candidate tumor suppressors is unknown...
  46. pmc Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy
    Nicholas E Power
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Urology 79:821-5. 2012
    ..To evaluate intravenous mannitol during minimally invasive partial nephrectomy (PN) by comparing the renal function outcomes of the patients who received it versus those who did not...
  47. doi request reprint Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters
    Preston C Sprenkle
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 61:593-9. 2012
    ..Indications for partial nephrectomy (PN) in the treatment of renal cell carcinoma are evolving, particularly for larger, more complex tumors...
  48. ncbi request reprint Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
    Premal H Patel
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 26:273-6. 2008
    ..Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial...
  49. ncbi request reprint Significance of peritumoral vascularity on CT in evaluation of renal cortical tumor
    Jingbo Zhang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Comput Assist Tomogr 31:717-23. 2007
    ..To investigate whether the presence and degree of peritumoral vascularity may provide any diagnostic information regarding the histological subtypes of renal tumors...
  50. ncbi request reprint Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors
    Cheryl T Lee
    Department of Urology, University of Michigan, 1500 E Medical Center Drive, Box 0330, Ann Arbor, MI 49109, USA
    Urol Oncol 21:179-84. 2003
    ..It may be reasonable to target RCC patients displaying altered bcl-2 levels for molecular therapies, such as anti-bcl2, should metastatic disease develop...
  51. pmc Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection
    Michael E Karellas
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 103:160-4. 2009
    ..To examine the effect of radical nephrectomy (RN) with adjacent organ and structure resection on survival, as invasion of adjacent organs in patients with renal cell carcinoma (RCC) is rare...
  52. doi request reprint Recovery of renal function after open and laparoscopic partial nephrectomy
    Ari Adamy
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 58:596-601. 2010
    ..Although oncologic outcomes appear to be similar after laparoscopic partial nephrectomy (LPN) and open partial nephrectomy (OPN), data on renal function are lacking...
  53. ncbi request reprint Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
    Robert J Motzer
    Geritourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:454-63. 2004
    ..To describe survival in previously treated patients with metastatic renal cell carcinoma (RCC) who are candidates for clinical trials of new agents as second-line therapy...
  54. ncbi request reprint Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex
    Mark E Snyder
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 176:2391-5; discussion 2395-6. 2006
    ....
  55. doi request reprint Sunitinib therapy in renal cell carcinoma
    Matthew F O'Brien
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 101:1339-42. 2008
  56. doi request reprint Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes
    Hebert Alberto Vargas
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 278E, New York, NY 10065, USA
    Radiology 264:779-88. 2012
    ..To investigate the use of quantitative multiphasic contrast material-enhanced magnetic resonance (MR) imaging in differentiating between common benign and malignant histologic subtypes of renal cortical tumors...
  57. doi request reprint Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55902, USA
    J Urol 182:2601-6. 2009
    ..We evaluated survival in patients with 4 to 7 cm renal tumors in a bi-institutional collaboration...
  58. doi request reprint Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
    David J Gallagher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 115:5193-201. 2009
    ..The objective of this study was to evaluate the feasibility and survival impact of adjuvant, sequential chemotherapy in patients with high-risk UC...
  59. pmc Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumors
    Joseph A Pettus
    Department of Urology, Wake Forest University Baptist Hospital, Medical Blvd, Winston Salem, NC 27157, USA
    Mayo Clin Proc 83:1101-6. 2008
    ..To evaluate the effect of baseline renal function and comorbidity index on survival in patients with renal tumors...
  60. doi request reprint Renal oncocytosis: management and clinical outcomes
    Ari Adamy
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 185:795-801. 2011
    ..We describe our experience with renal oncocytosis, focusing on management and outcomes...
  61. ncbi request reprint Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumours
    Eric O Kwon
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:286-9. 2007
    ....
  62. ncbi request reprint Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:1339-43; discussion 1343. 2006
    ..To provide data with which warm renal ischemia can be compared we analyzed short-term and long-term changes in the glomerular filtration rate after temporary cold renal ischemia...
  63. ncbi request reprint Perioperative clinical thromboembolic events after radical or partial nephrectomy
    Joseph A Pettus
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 68:988-92. 2006
    ..Cancer is an established risk factor for deep vein thrombosis (DVT) and pulmonary embolism (PE); however, their incidence after nephrectomy for renal tumors has been poorly studied...
  64. ncbi request reprint Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival
    J James Bruno
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 97:933-8. 2006
    ..To analyse the survival benefit of resecting local recurrence (LR) of renal cell carcinoma (RCC) in the presence and absence of concomitant metastasis...
  65. ncbi request reprint Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma
    Darren R Feldman
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Genitourin Cancer 6:25-30. 2008
    ..In this study, the efficacy and toxicity of pegylated IFN was assessed in patients with metastatic renal cell carcinoma (mRCC)...
  66. pmc Contemporary use of partial nephrectomy at a tertiary care center in the United States
    R Houston Thompson
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 181:993-7. 2009
    ..The use of partial nephrectomy for renal cortical tumors appears unacceptably low in the United States according to population based data. We examined the use of partial nephrectomy at our tertiary care facility in the contemporary era...
  67. doi request reprint Preoperative nomogram predicting 12-year probability of metastatic renal cancer
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 179:2146-51; discussion 2151. 2008
    ..We developed a predictive model that could be used in the preoperative setting...
  68. doi request reprint Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma
    Patrick E Teloken
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 182:2132-6. 2009
    ..We evaluated our experience with tumor histology in patients with localized renal cell carcinoma...
  69. ncbi request reprint Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma
    Beverly Drucker
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 21:341-5. 2003
    ..At the dose and schedule used in this trial, the lack of antitumor activity associated with ZD1839 does not support further study in patients with metastatic RCC...
  70. doi request reprint Radical nephrectomy with vena caval thrombectomy: a contemporary experience
    Matthew G Kaag
    Urology Service and Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 107:1386-93. 2011
    ..To report on the contemporary Memorial Sloan-Kettering Cancer Center experience with radical nephrectomy and vena caval thrombectomy...
  71. doi request reprint Partial nephrectomy for selected renal cortical tumours of ≥ 7 cm
    Michael E Karellas
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 106:1484-7. 2010
    ....
  72. pmc Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies
    William T Lowrance
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 105:16-20. 2010
    ....
  73. ncbi request reprint Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology
    Farhang Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:1057-61. 2004
    ..We determined the prognostic significance of renal vein or inferior vena caval (IVC) extension in patients with nonmetastatic renal cell carcinoma (RCC) or oncocytoma undergoing surgery...
  74. ncbi request reprint Phase II trial of bortezomib for patients with advanced renal cell carcinoma
    G Varuni Kondagunta
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:3720-5. 2004
    ..To assess the efficacy and toxicity of bortezomib (Velcade; Milennium Pharmaceuticals Inc, Cambridge, MA; formerly PS-341) in patients with metastatic renal cell carcinoma (RCC)...
  75. ncbi request reprint Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:177-81. 2003
    ..The impact of orthotopic urinary diversion on the quality of cystectomy and ensuing cancer control has not been adequately studied. We analyzed our experience with this clinical problem...
  76. ncbi request reprint Tumor location does not affect long-term renal function after partial nephrectomy
    Joseph A Pettus
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:1059-63. 2007
    ..To study the effect of central tumor location on the glomerular filtration rate (GFR) after partial nephrectomy for renal cortical tumor...
  77. ncbi request reprint Long-term follow-up of bilateral sporadic renal tumors
    Manish I Patel
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 61:921-5. 2003
    ..To assess the clinical characteristics, pathology, and long-term follow-up of patients with bilateral nonfamilial renal tumors (BNFRTs)...
  78. pmc Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size?
    Jordan M Kurta
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 103:24-7. 2009
    ..To evaluate the difference between radiographic size on computed tomography (CT) and the pathological size of renal tumours, in contemporary patients...
  79. ncbi request reprint Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
    Chaitanya R Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 8:304-10. 2007
    ..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...
  80. ncbi request reprint A postoperative prognostic nomogram for renal cell carcinoma
    M W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 166:63-7. 2001
    ..The nomogram may be useful for patient counseling, clinical trial design and patient followup planning...
  81. doi request reprint The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications
    Karim Touijer
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 57:214-22. 2010
    ....
  82. ncbi request reprint Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma
    Satish K Tickoo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1258-63. 2007
    ..We investigated the hypoxia inducible pathway marker immunohistochemical expression profile, and any potential therapeutic implications that such expression may have, in these tumors...
  83. pmc Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases
    Andrew Feifer
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 185:37-42. 2011
    ..To validate this presumed equivalence we compared patients with isolated muscular venous branch invasion to those with renal vein invasion and those with no confirmed vascular invasion...
  84. ncbi request reprint Mode of presentation of renal cell carcinoma provides prognostic information
    Cheryl T Lee
    Department of Urology, University of Michigan Hospitals, 1500 E Medical Center Drive, Box 0330, Ann Arbor, MI 48109, USA
    Urol Oncol 7:135-40. 2002
    ..Previous small series have suggested a prognostic benefit for incidental presentation. This study utilizes a large contemporary patient cohort to examine patterns of RCC presentation and their clinical implications...
  85. ncbi request reprint Solid renal cortical tumors: differentiation with CT
    Jingbo Zhang
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C278D, New York, NY 10021, USA
    Radiology 244:494-504. 2007
    ..To retrospectively determine if solid renal cortical tumors can be differentiated on computed tomographic (CT) images on the basis of their morphologic features and enhancement patterns...
  86. ncbi request reprint Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3193-8. 2002
    ..The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder...
  87. ncbi request reprint Natural history of chronic renal insufficiency after partial and radical nephrectomy
    James McKiernan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 59:816-20. 2002
    ..Elective PN for renal tumors is intended to preserve renal function; however, studies of transplant donors suggest normal renal function is also maintained after unilateral nephrectomy...
  88. ncbi request reprint Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2376-81. 2002
    ..To define outcome data for patients with metastatic renal cell carcinoma (RCC) with histology other than clear-cell type, including collecting duct (or medullary carcinoma), papillary, chromophobe, and unclassified histologies...
  89. ncbi request reprint Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors
    Farhang Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2370-5. 2002
    ....
  90. pmc Evaluation of renal masses with contrast-enhanced ultrasound: initial experience
    Scott Gerst
    Department of Radiology, Breast and Imaging Center, Memorial Sloan Kettering Cancer Center, 300 E 66th St, Rm 705, New York, NY 10065, USA
    AJR Am J Roentgenol 197:897-906. 2011
    ..This prospective study was performed to determine whether preoperative IV microbubble contrast-enhanced ultrasound can be used to differentiate indolent and benign renal tumors from more aggressive clear cell carcinoma...
  91. ncbi request reprint Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 20:289-96. 2002
    ..The data can be applied to design and interpretation of clinical trials of new agents and treatment programs against this refractory malignancy...
  92. ncbi request reprint A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes
    Vivian E Strong
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Surg Endosc 22:386-91. 2008
    ..These PET probes are handheld, allowing for real-time evaluation of cancer using a tool that provides surgeons with better intraoperative assessment of tumor sites...
  93. ncbi request reprint Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm
    Atreya Dash
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 97:939-45. 2006
    ..To compare the outcomes of patients who had a elective partial nephrectomy (PN) or radical nephrectomy (RN) for clear cell renal cell carcinoma (RCC) of 4-7 cm...
  94. doi request reprint Hereditary and familial kidney cancer
    Jonathan A Coleman
    Department of Surgery Urology Division, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 19:478-85. 2009
    ..The purpose of this review is to familiarize the reader with the known heritable forms of kidney cancer, the recent advances in the field and their impact on patient management...
  95. ncbi request reprint Impact of body mass index on survival of patients with surgically treated renal cell carcinoma
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 175:46-52. 2006
    ..We evaluated the impact of BMI and other clinical/pathological characteristics on survival in patients with RCC treated with radical or partial nephrectomy...
  96. ncbi request reprint Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:1474-7. 2004
    ..In a cohort of patients who underwent exploratory laparotomy for unsuspected metastatic GCT we determined the impact of this surgery on morbidity, therapeutic delay and cancer therapy...
  97. doi request reprint Incidental angiomyolipoma resected during renal surgery for an enhancing renal mass
    Ryan K Berglund
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 104:1650-4. 2009
    ....
  98. ncbi request reprint Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance
    F Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:94-100. 2001
    ....
  99. ncbi request reprint Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells
    V M Richon
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 57:2789-98. 1997
    ....
  100. doi request reprint A case of port-site recurrence and locoregional metastasis after laparoscopic partial nephrectomy
    Timothy A Masterson
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 5:345-9. 2008
    ..5 cm right renal mass, pathologically confirmed as type 2 papillary renal cell carcinoma (RCC). Two years later he was referred to a specialist oncology center after routine follow-up raised suspicion for metastatic disease...
  101. ncbi request reprint Long-term response with sunitinib for metastatic renal cell carcinoma
    Ellen A Ronnen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 68:672.e19-20. 2006
    ..This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma...